Immune checkpoint inhibition in melanoma
|
|
- Hugh Carr
- 6 years ago
- Views:
Transcription
1 Immune checkpoint inhibition in melanoma John Haanen ESMO Preceptorship Zürich 217
2 Disclosures I have provided consultation, attended advisory boards, and/or provided lectures for: Pfizer, MSD, BMS, IPSEN, Roche/Genentech, NEON Therapeutics, Novartis for which NKI received honoraria Through my work NKI received grant support from BMS, MSD, Novartis I declare no conflict of interest
3 Immune Checkpoint inhibitors Immune checkpoints play an important role in immune tolerance Cancer hijacks many of these peripheral tolerance mechanism to escape the immune system Inhibition of a single immune checkpoint can be enough to break this cancer induced tolerance (anti-ctla4, anti-pd- 1/PD-L1) Combination of these inhibitors appear more powerful
4 Melanoma has become from a disease that gave cancer a bad name to a model disease for I-O Current I-O treatment options for melanoma Stage IIII disease Neo-adjuvant/adjuvant trials Unresectable stage IIIc and stage IV disease
5
6 EORTC 1871/CA184-29: Study Design Randomized, double-blind, phase 3 study evaluating the efficacy and safety of ipilimumab in the adjuvant setting for high-risk melanoma High-risk, stage III, completely resected melanoma R N = 475 INDUCTION Ipilimumab 1 mg/kg Q3W 4 MAINTENANCE Ipilimumab 1 mg/kg Q12W up to 3 years N = 951 N = 476 INDUCTION Placebo Q3W 4 MAINTENANCE Placebo Q12W up to 3 years Week 1 Week 12 Week 24 Stratification factors Stage (IIIA vs IIIB vs IIIC 1-3 positive lymph nodes vs IIIC 4 positive lymph nodes) Regions (North America, European countries, and Australia) Enrollment Period: June 28 to July 211 Treatment up to a maximum of 3 years, or until disease progression, intolerable toxicity, or withdrawal Q3W = every 3 weeks; Q12W = every 12 weeks; R = randomization.
7 Baseline Patient Characteristics Ipilimumab (n = 475) Placebo (n = 476) Median age, years Male, % ECOG PS /1, % 94/6 94/6 Stage, % IIIA IIIB IIIC with 1-3 positive LN IIIC with 4 positive LN vs 2-3 vs 4 positive LN, % 46 vs 34 vs 2 46 vs 33 vs 21 LN involvement, % Microscopic Macroscopic Ulceration of primary, % ECOG PS = Eastern Cooperative Oncology Group performance status; LN = lymph node.
8 Patients Alive and Without Recurrence (%) RFS (per IRC) Ipilimumab Placebo Events/patients 264/ /476 HR (95% CI) a.76 (.64,.89) Log-rank P value a.8 Median RFS, months (95% CI) 41% 3% 27.6 (19.3, 37.2) 17.1 (13.6, 21.6) a Stratified by stage provided at randomization. CI = confidence interval O N Number of patients at risk Years Ipilimumab Placebo
9 OS Patients Alive (%) Ipilimumab Placebo Deaths/patients 162/ /476 HR (95.1% CI) a.72 (.58,.88) Log-rank P value a.1 65% 54% a Stratified by stage provided at randomization O N Number of patients at risk Years Ipilimumab Placebo
10 Patient Disposition and Treatment Ipilimumab (n = 471) Placebo (n = 474) Discontinuation, % 1 1 Reasons for discontinuation, % Normal completion (received study drug for entire 3 years) Disease recurrence AE related to study drug Other reasons a Median doses, per patient, n Receiving 1 maintenance dose, % Receiving 7 doses (1 year of therapy), % a Includes AE unrelated to study drug, both related and unrelated to study drug, patient request, poor/noncompliance, death, pregnancy, patient no longer eligible, other.
11 Phase III trials in the adjuvant setting for stage III and IV disease A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate-238) Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group (KEYNOTE-54) A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients With High Risk Resected Melanoma
12 Adjuvant Therapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage III/IV Melanoma: A Randomized, Double-blind, Phase 3 Trial (CheckMate 238) Jeffrey Weber, 1 Mario Mandala, 2 Michele Del Vecchio, 3 Helen Gogas, 4 Ana M. Arance, 5 C. Lance Cowey, 6 Stéphane Dalle, 7 Michael Schenker, 8 Vanna Chiarion-Sileni, 9 Ivan Marquez-Rodas, 1 Jean-Jacques Grob, 11 Marcus Butler, 12 Mark R. Middleton, 13 Michele Maio, 14 Victoria Atkinson, 15 Paola Queirolo, 16 Veerle de Pril, 17 Anila Qureshi, 17 James Larkin, 18 * Paolo A. Ascierto 19 * 1 NYU Perlmutter Cancer Center, New York, New York, USA; 2 Papa Giovanni XIII Hospital, Bergamo, Italy; 3 Medical Oncology, National Cancer Institute, Milan, Italy; 4 University of Athens, Athens, Greece; 5 Hospital Clínic de Barcelona, Barcelona, Spain; 6 Texas Oncology-Baylor Cancer Center, Dallas, Texas, USA; 7 Hospices Civils de Lyon, Pierre Bénite, France; 8 Oncology Center Sf Nectarie Ltd., Craiova, Romania; 9 Oncology Institute of Veneto IRCCS, Padua, Italy; 1 General University Hospital Gregorio Marañón, Madrid, Spain; 11 Hôpital de la Timone, Marseille, France; 12 Princess Margaret Cancer Centre, Toronto, Ontario, Canada; 13 Churchill Hospital, Oxford, United Kingdom; 14 Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; 15 Gallipoli Medical Research Foundation and Princess Alexandra Hospital, Woolloongabba, and University of Queensland, Greenslopes, Queensland, Australia; 16 IRCCS San Martino-IST, Genova, Italy; 17 Bristol-Myers Squibb, Princeton, New Jersey, USA; 18 Royal Marsden NHS Foundation Trust, London, UK; 19 Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy; *Contributed equally to this study.
13 CA29-238: CA29-67: Study Design Patients with high-risk, completely resected stage IIIB/IIIC or stage IV melanoma Stratified by: 1:1 n = 453 n = 453 1) Disease stage: IIIB/C vs IV M1a-M1b vs IV M1c 2) PD-L1 status at a 5% cutoff in tumor cells NIVO 3 mg/kg IV Q2W and IPI placebo IV Q3W for 4 doses then Q12W from week 24 IPI 1 mg/kg IV Q3W for 4 doses then Q12W from week 24 and NIVO placebo IV Q2W Follow-up Maximum treatment duration of 1 year Enrollment period: March 3, 215 to November 3, 215
14 Study Overview Primary endpoint RFS: time from randomization until first recurrence (local, regional, or distant metastasis), new primary melanoma, or death Secondary endpoints OS Safety and tolerability RFS by PD-L1 tumor expression HRQoL Current interim analysis Primary endpoint (RFS), safety, and HRQoL DMFS (exploratory) Duration of follow-up: minimum 18 months; 36 events DMFS = distant metastasis-free survival; HRQoL = health-related quality of life
15 Baseline Patient Characteristics NIVO (n = 453) IPI (n = 453) Median age, years Male, % Stage, IIIB+IIIC, % Macroscopic lymph node involvement (% of stage IIIB+IIIC) 6 58 Ulceration (% of stage IIIB+IIIC) Stage IV, % M1c without brain metastases (% stage IV) PD-L1 expression 5%, % BRAF mutation, % LDH ULN, % Most of the patients had cutaneous melanoma (85%), and 4% had acral and 3% had mucosal melanoma All 95 patients are off treatment; median doses were 24 (1-26) in the NIVO group and 4 (1-7) in the IPI group 397 patients completed 1 year of treatment (61% of the NIVO group and 27% of the IPI group)
16 Primary Endpoint: RFS NIVO IPI 1 Events/patients 154/453 26/ Median (95% CI) NR NR (16.6, NR) HR (97.56% CI).65 (.51,.83) Log-rank P value <.1 RFS (%) % 61% 66% 53% NIVO IPI Months Number of patients at risk NIVO IPI
17 Subgroup Analysis of RFS: PD-L1 Expression Level PD-L1 Expression Level <5% PD-L1 Expression Level 5% NIVO IPI NIVO IPI Events/patients 114/ /286 Events/patients 31/152 57/154 Median (95% CI) NR 15.9 (1.4, NR) Median (95% CI) NR NR 1 HR (95% CI).71 (.56,.91) 1 HR (95% CI).5 (.32,.78) % 8 8 RFS (%) % 54% RFS (%) % NIVO IPI 2 1 NIVO IPI Number of patients at risk Months Number of patients at risk Months NIVO NIVO IPI IPI
18 RFS: Prespecified Subgroups Subgroup No. of events/no. of patients NIVO 3 mg/kg IPI 1 mg/kg Unstratified HR (95% CI) Overall Overall 154/453 26/ (.53,.81) Age <65 years 16/ / (.51,.84) 65 years 48/12 59/ (.45,.97) Sex Male 99/ / (.53,.88) Female 55/195 73/ (.44,.89) Stage (CRF) Stage IIIb 41/163 54/ (.44, 1.) Stage IIIc 79/24 19/ (.49,.87) Stage IV M1a-M1b 25/62 35/66.63 (.38, 1.5) Stage IV M1c 8/2 8/21 1. (.37, 2.66) Not reported 1/2 / Stage III: Ulceration Absent 58/21 94/ (.42,.82) Stage III: Lymph node involvement Present 6/153 64/ (.51, 1.4) Not reported 2/15 5/15.39 (.7, 2.) Microscopic 41/125 55/ (.47, 1.7) Macroscopic 72/219 11/ (.46,.84) Not reported 7/25 7/18.6 (.21, 1.72) PD-L1 status <5%/indeterminate 123/3 149/ (.56,.9) 5% 31/152 57/154.5 (.32,.78) BRAF mutation status Mutant 63/187 84/ (.52, 1.) Wild-type 67/197 15/ (.43,.79) Not reported 24/69 17/45.83 (.45, 1.54) Unstratified HR (95% CI) 1 2 NIVO IPI
19 Exploratory Endpoint: DMFS for Stage III Patients NIVO IPI % Events/patients 93/ /366 Median (95% CI) NR NR HR (95% CI).73 (.55,.95) Log-rank P value.24 DMFS (%) % Number of patients at risk NIVO IPI NIVO IPI Months
20 Treatment-Related Select Adverse Events NIVO (n = 452) IPI (n = 453) AE, n (%) Any grade Grade 3/4 Any grade Grade 3/4 Skin 21 (44.5) 5 (1.1) 271 (59.8) 27 (6.) Gastrointestinal 114 (25.2) 9 (2.) 219 (48.3) 76 (16.8) Hepatic 41 (9.1) 8 (1.8) 96 (21.2) 49 (1.8) Pulmonary 6 (1.3) 11 (2.4) 4 (.9) Renal 6 (1.3) 7 (1.5) Hypersensitivity/infusion reaction 11 (2.4) 1 (.2) 9 (2.) Endocrine Adrenal disorder 6 (1.3) 2 (.4) 13 (2.9) 4 (.9) Diabetes 2 (.4) 1 (.2) 1 (.2) Pituitary disorder 8 (1.8) 2 (.4) 56 (12.4) 13 (2.9) Thyroid disorder 92 (2.4) 3 (.7) 57 (12.6) 4 (.9) Median time to onset of treatment-related select AEs was generally shorter for patients receiving IPI (range weeks) than for those receiving NIVO (range weeks)
21 Conclusions Nivolumab showed a clinically and statistically significant improvement in RFS vs the active control of high-dose ipilimumab for patients with resected stages IIIB/IIIC and stage IV melanoma at high risk of recurrence (HR =.65, P <.1) 18-month RFS rates were 66% for nivolumab and 53% for ipilimumab Benefit for nivolumab was observed across the majority of prespecified subgroups tested, including PD-L1 and BRAF mutation status Nivolumab has a superior safety profile in comparison with ipilimumab, with fewer grade 3/4 AEs and fewer AEs leading to treatment discontinuation Nivolumab has the potential to be a new standard treatment option for patients with resected stage IIIB, IIIC, and IV melanoma regardless of BRAF mutation
22 New developments in adjuvant and neoadjuvant trials An Open-label, Phase IB Study of NEO-PV-1 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder Phase II Study to Identify the Optimal neoadjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients (OPACIN-neo) A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V6 Mutant Resectable Stage IIIB/C Melanoma A Phase 1b Trial of Neoadjuvant CXCR4 antagonist (X4P- 1) Alone and With Pembrolizumab in Patients With Resectable Melanoma
23 Melanoma has become from a disease that gave cancer a bad name to a model disease for I-O Current I-O treatment options for melanoma Stage IIII disease Neo-adjuvant/adjuvant trials Unresectable stage IIIc and stage IV disease
24 Anti-CTLA-4 Ipilimumab: 4 infusions for the induction Pre-treated-pts +/- gp1 HLA-A2 3mg/kg Re-induction possible naive-pts + DTIC 1 mg/kg Maintenance possible Hodi et al 21 NEJM Robert et al NEJM 211
25 Pooled OS Analysis of ipilimumab treated 4846 patients (incl EAP) Median OS (95% CI): 9.5 (9. 1.) 3-year OS rate (95% CI): 21% (2 22%) Schadendorf et al., J Clin Oncol 215
26 Anti-PD1 Demonstrates Broad Antitumor Activity Change From Baseline in Tumor Size, % Melanoma 1 (N=655) KEYNOTE NSCLC 2 (N=262) KEYNOTE H&N 3 (N=132) KEYNOTE Urothelial 4 (N=33) KEYNOTE Gastric 5 (N=39) KEYNOTE-12 1 TNBC 6 (N=32) KEYNOTE-12 1 chl 7 (N=29) KEYNOTE-13 1 Mesothelioma 8 (N=25) KEYNOTE-28 1 Ovarian 9 (N=26) KEYNOTE-28 1 SCLC 1 (N=2) KEYNOTE-28 1 Esophageal 11 (N=23) KEYNOTE Courtesy of G Long 1. Daud A et al. 215 ASCO; 2. Garon EB et al. ESMO 214; 3. Seiwert T et al. 215 ASCO; 4. Plimack E et al. 215 ASCO; 5. Bang YJ et al. 215 ASCO; 6. Nanda R et al. SABCS 214; 7. Moskowitz C et al. 214 ASH Annual Meeting; 8. Alley EA et al. 215 AACR; 9. Varga A et al. 215 ASCO; 1. Ott PA et al. 215 ASCO; 11. Doi T et al. 215 ASCO.
27 CheckMate-66 Robert et al., NEJM 215
28 Updated OS results from CheckMate 66 trial in BRAF wt advanced melanoma Decrease of the risk of death 58% vs chemotherapy Atkinson et al. abstract 3774 SMR 215
29 OS after ipilimumab start as 2 nd line treatment
30 Pembrolizumab vs ipilimumab Treatment Arm Median (95% CI), mo Rate at 12 mo HR (95% CI) P Pembrolizumab Q2W NR (NR-NR) 74.1%.63 ( ) <.1 Pembrolizumab Q3W NR (NR-NR) 68.4%.69 (.52-.9) <.1 Ipilimumab NR (12.7-NR) 58.2% Decrease of risk of death of pembrolizumab 31 to 37% vs ipilimumab Robert et al NEJM 215
31 ANALYSIS OF RESPONSE AND SURVIVAL IN PATIENTS WITH IPILIMUMAB- REFRACTORY MELANOMA TREATED WITH PEMBROLIZUMAB IN KEYNOTE-2 A. Daud 1 ; I. Puzanov 2 ; R. Dummer 3 ; D. Schadendorf 4 ; O. Hamid 5 ; C. Robert 6 ; F. S. Hodi 7 ; J. Schachter 8 ; J. A. Sosman 9 ; A. C. Pavlick 1 ; R. Gonzalez 11 ; C. Blank 12 ; L. D. Cranmer 13 ; S. J. O Day 14 ; A. K.Salama 15 ; K. A. Margolin 16 ; J. Yang 17 ; B. Homet Moreno 17 ; N. Ibrahim 17 ; A. Ribas 18 1 University of California, San Francisco, San Francisco, CA, USA; 2 Vanderbilt-Ingram Cancer Center, Nashville, TN, USA; (currently at Roswell Park Cancer Institute, Buffalo, NY, USA; 3 University of Zürich, Zürich, Switzerland; 4 University Hospital Essen, Essen, Germany; 5 The Angeles Clinic and Research Institute, Los Angeles, CA, USA; 6 Gustave Roussy and Paris-Sud University, Villejuif, France; 7 Dana- Farber Cancer Institute, Boston, MA, USA; 8 Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel; 9 Vanderbilt- Ingram Cancer Center, Nashville, TN, USA (currently at Northwestern University Feinberg School of Medicine, Chicago, IL, USA, USA); 1 New York University Cancer Institute, New York, NY, USA; 11 University of Colorado Denver, Aurora, CO, USA; 12 Netherlands Cancer Institute, Amsterdam, Netherlands; 13 currently at University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA; 14 John Wayne Cancer Institute, Santa Monica, CA, USA; 15 Duke Cancer Institute, Durham, NC, USA; 16 City of Hope, Duarte, CA, USA; 17 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; 18 University of California, Los Angeles, Los Angeles, CA, USA 31
32 Time to and Duration (RECIST v1.1, INV) of Complete Response to Pembrolizumab Patients with CR, n = 29 Median, mo (range) Time to CR 2.9 ( ) Time from SD to CR (n = 5) 6.9 ( ) Time from PR to CR ( n = 21) 8. ( ) Duration of CR Not reached ( ) Arrows indicate conversion from SD to CR; 5 patients converted from SD and 21 from PR to CR. Median DOR in all treated patients was not reached (range mo to mo). Of 2 patients without PD, 14 discontinued because of AEs (n = 3) or patient/physician decision (n = 11). Data cut-off: February 3, 217.
33 Time to and Duration (RECIST v1.1, INV) of Partial Response to Pembrolizumab Duration (RECIST v1.1, INV) of Stable Disease to Pembrolizumab Patients with PR, n = 7 Median, mo (range) Time to PR 2.9 ( ) Time from SD to PR (n = 28) 2.7 ( ) Duration of PR Not reached (1.9+ to 43.5+) Patients with SD, n = 88 Median, mo (range) a Duration of SD 6.9 (.8+ to 38.8+) Arrows indicate conversion from SD to PR; 28 patients converted from SD to PR. Median DOR in all treated patients was not reached (range mo to mo). Of 42 patients without PD, 29 discontinued because of AEs (n = 15) or physician/patient decision (n = 14). Data cut-off: February 3, 217. Of 25 patients without PD, 24 discontinued because of AEs (n = 11) or patient/physician decision (n = 13). a Duration of SD is from randomization to progression. Data cut-off: February 3, 217.
34 PFS AND OS in All Pembrolizumab-Treated Patients and Those With Best Response of CR, PR, or SD Group Events, n Median, mo (95% CI) Group Events, n Median, mo (95% CI) CR (38.9-NR) CR 29 NR (NR-NR) PR (27.9 -NR) PR 7 NR (NR-NR) 1 SD All treated ( ) 4.2 ( ) 1 SD All treated ( ) 14. ( ) P F S, % % 76% 24% 29% 75% 66% 6% 21% 72% 49% 1% 16% O S, % % 96% 71% 55% 93% 86% 31% 37% 89% 71% 24% 3% No. at risk Time, months No. at risk Time, months NR, not reached. PFS was assessed by RECIST v1.1 per investigator. Data cut-off: February 3, 217.
35 Conclusions Responses to pembrolizumab are durable and associated with prolonged OS in ipilimumab-refractory melanoma Even in these heavily pretreated patients, best response can evolve over time, with late conversions from SD to PR/CR and PR to CR observed No new safety signals with longer term follow-up
36 Keynote 1: phase I study of pembrolizumab in 655 metastatic melanoma patients. Median follow-up of 43 months All Patients Treatment Naive a 1 9 Pts, N Events, n Median (95% CI) 1 9 Pts, N Events, n Median (95% CI) Overall Survival, % (59%) 23.8 mo ( mo) 42% 37% Overall Survival, % (5%) 41.2 mo (27.2 mo-nr) 51% 48% Time, months Time, months No. at risk No. at risk Robert et al EADO 217 a Excludes patients with ocular melanoma. Analysis cutoff date: September 1, 216.
37 Pembrolizumab phase 1: Keynote 1 : Median Follow-Up 43 Months for 655 patients Consent withdrawal 5% On treatment: 16% Discontinue for physician Decision 11% Discontinued for PD: 42% Discontinued for AEs: 25% Range of follow-up: months. Analysis cutoff date: September 1, 216. Robert et al EADO 217
38 Complete Responders: Disposition Median follow-up: 43 months 92 (88%) remained in CR a 15 (16%) patients had CR per irrc by investigator review 14 (13%) remained on pembrolizumab 24 (23%) discontinued for AEs (n = 12), PD (n = 2), or other reason (n = 1) 67 (64%) stopped pembrolizumab for observation Robert et al EADO 217 a Patient was alive and without disease progression. Analysis cutoff date: September 1, 216.
39 Complete Responders Who Stopped Pembrolizumab for Observation (N = 67) Median time to CR: 13 mo ( 3-36 mo) 61 (91%) responses were maintained Median response duration: NR (6+ to 56+ mo) Time to PD or last assessment Last dose CR PR PD Time to death Time, months Total bar length represents the time to the last scan. Analysis cutoff date: September 1, 216.
40 Complete Responders Who Stopped Pembrolizumab for Observation (N = 67) 2 patients died; causes unrelated to pembrolizumab (3,6) Only 4 patients experienced PD 2 received commercial pembrolizumab, and had PD (1, 4) 2 received 2 nd course pembrolizumab 1 had PR and is ongoing (2) 1 had PD (5) Time to PD or last assessment Last dose CR Time, months PR PD Time to death Robert et al EADO 217 Total bar length represents the time to the last scan. Analysis cutoff date: September 1, 216.
41 How long to treat with anti-pd1? In case of a partial response or stable disease? 41
42 KEYNOTE-6 (NCT ) Study Design Patients Unresectable, stage III or IV melanoma 1 previous therapy, excluding anti CTLA-4, PD-1, or PD-L1 agents Known BRAF mutation status a ECOG PS -1 No active brain metastases No serious autoimmune disease R 1:1:1 Pembrolizumab 1 mg/kg intravenous Q2W for 2 years Pembrolizumab 1 mg/kg intravenous Q3W for 2 years Ipilimumab 3 mg/kg intravenous Q3W 4 doses Stratification Factors ECOG PS ( vs 1) Line of therapy (first vs second) PD-L1 status b (positive vs negative) Primary end points: PFS and OS Secondary end points: ORR, duration of response, safety a Prior anti-braf targeted therapy was not required for patients with normal LDH levels and no clinically significant tumor-related symptoms or evidence of rapidly progressing disease. b Defined as 1% staining in tumor and adjacent immune cells as assessed by IHC (22C3 antibody).
43 Keynote 6: Patients Who Completed Protocol-Specified Time on Pembrolizumab a (median follow-up, 9.7 mo) 556 patients received pembrolizumab 14 (19%) completed pembrolizumab 24 (23%) CR 68 (65%) PR 12 (12%) SD 23 ongoing responses 1 PD b 1 received second course of pembrolizumab 64 ongoing responses 4 PD b 3 received second course of pembrolizumab 1 ongoing SD 2 deaths b,c C Robert et al ASCO 217 a Includes patients completing 21.6 months of treatment. b From end of pembrolizumab treatment. c Both deaths were a result of PD. Data cutoff date: Nov 3, 216.
44 PFS (irrc, investigator) from last Pembrolizumab dose in patients who completed protocol-specified time on treatment (n = 14) 1 9 Progression-Free Survival, % Patients who completed protocol-specified time on pembrolizumab, n Estimated PFS, % (95% CI) Median PFS (8-96) NR 12 (98%) patients were alive after a median of 9.7 months after completing pembrolizumab treatment No. at risk Time, months C Robert et al ASCO 217 Data cutoff date: Nov 3, 216.
45 Do we treat for too long? What is the risk? Late Adverse events with anti-pd1? Weber et al J Clin Oncol 217
46 n (%) No Significant increase in AE incidence between 2 and 3 years with anti-pd1 TREATMENT-RELATED AE INCIDENCE OVER TIME Pembrolizumab N = 555 Median FU (months) Any grade % Grade ¾ % Led to death % <1 Led to discontinuation % Data from Ribas et al, AACR 215; Robert et al ASCO 216; Robert et al ASCO 217 Analysis includes all randomized patients who received 1 pembrolizumab dose. a As designated by the investigator. b Because of sepsis. Data cutoff date: Nov 3, 216.
47 When can we stop anti-pd1? Help from PFS curve Ugurel S et al Eur J Cancer 217
48 Keynote 6 PFS Total Population (Median Follow-Up, 33.9 mo) 1 Stop pembro 9 8 Progression-Free Survival, % % 15% 31% 14% Pembrolizumab 2 1 Ipilimumab No. at risk Pembrolizumab Ipilimumab Time, months C Robert et al ASCO 217
49 Conclusion The optimal duration of immunotherapy is presently unknown Encouraging data: documentation of long term benefit after discontinuation in CR or after two years of treatment with anti-pd1 monotherapy (pembrolizumab) Randomized discontinuation trial needed but challenging to organize Practically: decision should be based upon patient s clear information and decision In case discontinuation due to toxicity and when the disease is not progressing, we advise not to rechallenge In case of confirmed CR after at least 6 months of therapy, if patients agree, we propose to stop In case of PR or SD, if patients agree, we propose to stop after 2 years
Immune checkpoint inhibition in melanoma. John Haanen
Immune checkpoint inhibition in melanoma John Haanen ESMO Preceptorship Singapore 217 Immune Checkpoint inhibitors Immune checkpoints play an important role in immune tolerance Cancer hijacks many of these
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationMelanoma: novità ESMO 2017
Melanoma: novità ESMO 2017 Vincenzo Picone Istituto dermopatico dell Immacolata (IDI) AGENDA Metastatico CheckMate 067 Adiuvante LBA7_PR - BRIM8: a randomized, double-blind, placebo-controlled study of
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationLA QUARTA ARMA CONTRO IL CANCRO
LA QUARTA ARMA CONTRO IL CANCRO Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure Employment or
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationOverall Survival (OS) Analysis From an Expanded Access Program (EAP) of Nivolumab (NIVO) in Combination with Ipilimumab (IPI) in Patients with Advanced Melanoma (MEL) David Hogg, Paul B. Chapman, 2 Mario
More informationMELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone
MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationCancer Immunotherapy: an Emerging Paradigm
Cancer Immunotherapy: an Emerging Paradigm Branimir I. Sikic, MD Professor of Medicine Stanford University Nevada Cancer Control Summit Reno, November 6, 217 T-Cell Response: Second Signals to Accelerate
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationÍndice. Melanoma Cáncer de Pulmón Otros tumores
Índice Melanoma Cáncer de Pulmón Otros tumores Carcinoma de Vejiga Carcinoma de Células Renales Carcinoma de Cabeza y Cuello Carcinomas del tubo digestivo Cáncer de Mama MELANOMA CIRUGÍA CIRUGÍA + INFa
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationA Phase 2 Study of Glembatumumab Vedotin, an Antibody Drug Conjugate Targeting gpnmb, in Advanced Melanoma
A Phase 2 Study of Glembatumumab Vedotin, an Antibody Drug Conjugate Targeting gpnmb, in Advanced Melanoma Patrick A. Ott, MD, PhD 1, Anna C. Pavlick, DO 2, Douglas B. Johnson, MD 3, Lowell Hart, MD 4,
More informationUniversity of California Los Angeles, Los Angeles, CA; 2. Department of Dermatology, University of Kiel, Kiel, Germany;
Final Efficacy Results of A3671009, a Phase III Study of Tremelimumab vs Chemotherapy (Dacarbazine or Temozolomide) in First-line Patients With Unresectable Melanoma Antoni Ribas, 1 Axel Hauschild, 2 Richard
More informationReview of immunotherapy in melanoma
Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationfor patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationREVISION DE LOS DATOS ACTUALES DE INMUNOTERAPIA EN MELANOMA. Miguel Ángel Cabrera Suárez Oncología médica HUNSC
REVISION DE LOS DATOS ACTUALES DE INMUNOTERAPIA EN MELANOMA Miguel Ángel Cabrera Suárez Oncología médica HUNSC Inmunoterapia en Melanoma Miguel Ángel Cabrera Suárez Oncologia médica HUNSC EL PASADO:
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationOverall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib () or ENCO in BRAF-Mutant Melanoma, Paolo A. Ascierto, Helen J. Gogas, Ana Arance, Mario Mandala,
More informationMelanoma BRAF mutado y terapias dirigidas. Javier Medina Martínez Hospital Virgen de la Salud, Toledo
Melanoma BRAF mutado y terapias dirigidas Javier Medina Martínez Hospital Virgen de la Salud, Toledo Enfermedad avanzada: Seguimiento a largo plazo Retratamiento Metástasis cerebrales Adyuvancia November-2017
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationNCCN Guidelines for Cutaneous Melanoma V Meeting on 06/20/18
ME-1, ME-3, ME-B Submission from Castle Biosciences, Inc (05/30/18) to consider inclusion of the DecisionDx-Melanoma test in the guidelines as a prognostic test that provides stratification according to
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationAppendices. Appendix A Search terms
Appendices Appendix A Search terms Database Search terms Medline 1. Ipilimumab; 2. MDX-010; 3. MDX-101; 4. Yervoy; 5. BMS-734016; 6. Nivolumab; 7. ONO-4538; 8. BMS-936558; 9. MDX-1106; 10. Opdivo; 11.
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationAdjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Original Article Adjuvant versus in Resected Stage III or IV Melanoma J. Weber, M. Mandala, M. Del Vecchio, H.J. Gogas, A.M. Arance, C.L. Cowey, S. Dalle, M. Schenker, V. Chiarion-Sileni, I. Marquez-Rodas,
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationTHE FUTURE OF MELANOMA MANAGEMENT
THE FUTURE OF MELANOMA MANAGEMENT CHARLES M. BALCH, MD, FACS PROFESSOR OF SURGERY UNIV. OF TEXAS MD ANDERSON CANCER CENTER HOUSTON, TEXAS UNIV. OF TEXAS SOUTHWESTERN MEDICAL CENTER DALLAS, TEXAS Editor-in-Chief,
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationUpdates From ASCO in Melanoma Immuno-Oncology. Adil Daud, MBBS University of California San Francisco San Francisco, California
Updates From ASCO in Melanoma Immuno-Oncology Adil Daud, MBBS University of California San Francisco San Francisco, California 3-Year Overall Survival for Patients With Advanced Melanoma Treated With Pembrolizumab
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationUnmet Need Mucosal and Uveal Melanoma
Unmet Need Mucosal and Uveal Melanoma Matteo Carlino Crown Princess Mary Cancer Centre Westmead and Blacktown Hospitals Melanoma Institute Australia The University of Sydney. Cutaneous Overall Survival
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationMelanoma Update Lynn Schuchter, MD Abramson Cancer Center University of Pennsylvania
Melanoma Update 2016 Lynn Schuchter, MD Abramson Cancer Center University of Pennsylvania ASCO 2016 ABSTRACT # STUDY ID AGENT OUTCOME PRESENTER 9503 KEYNOTE 001 PEMBRO 3 YR OS, PFS, ORR 9504 KEYNOTE 006
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationPresenter Disclosure Information
Presenter Disclosure Information Tara C. Gangadhar, M.D. The following relationships exist related to this presentation: Research funding (Institution): Incyte Corporation and Merck & Co., Inc Preliminary
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationASCO / COLUMBUS ENCORE PRESENTATION June 4, 2018
ASCO / COLUMBUS ENCORE PRESENTATION June 4, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions of the Private
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationToxicity from Checkpoint Inhibitors. James Larkin FRCP PhD
Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures Research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): BMS, Eisai, GSK, MSD, Novartis, Pfizer, Roche/Genentech
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationCutaneous melanoma: new developments for 2018
Cutaneous melanoma: new developments for 2018 and beyond KIM MARGOLIN, M.D., FASCO CITY OF HOPE MEDICAL ONCOLOGY CORONADO, CALIFORNIA SEPTEMBER 20, 2018 DISCLOSURE Consultant for ImaginAb, Nektar Therapeutics,
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationRevolution in der adjuvanten Therapie des Melanoms? Was bleibt? Was wird sich verändern?
Revolution in der adjuvanten Therapie des Melanoms? Was bleibt? Was wird sich verändern? Dr. Peter Mohr, Elbeklinikum Buxtehude Hautkrebszentrum Oktober 217 Approved treatments for melanoma in the adjuvant
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationLESSONS LEARNT Melanoma Academic Perspective
LESSONS LEARNT Melanoma Academic Perspective Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosures
More informationNew treatments in melanoma
New treatments in melanoma Paolo A. Ascierto, MD Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationNew Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy
New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationLuana Calabrò Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY
4 TH International Conference Traslational Research in Oncology Forli, November 10, 2016 Cytotoxic T-lymphocyte antigen-4 (CTLA-4) Luana Calabrò Medical Oncology and Immunotherapy, University Hospital
More informationAlpelisib (ALP) + Fulvestrant (FUL) for Advanced Breast Cancer (ABC): Phase 3 SOLAR-1 Trial Results
Alpelisib (ALP) + Fulvestrant (FUL) for Advanced Breast Cancer (ABC): Phase 3 SOLAR-1 Trial Results Dejan Juric, 1* Eva Maria Ciruelos, 2 Gabor Rubovszky, 3 Mario Campone, 4 Sibylle Loibl, 5 Hope S. Rugo,
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationMetastasectomy for Melanoma What s the Evidence and When Do We Stop?
Metastasectomy for Melanoma What s the Evidence and When Do We Stop? Vernon K. Sondak, M D Chair, Moffitt Cancer Center Tampa, Florida Focus on Melanoma London, UK October 15, 2013 Disclosures Dr. Sondak
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More information